Yahoo
LSE - Delayed Quote GBp

Poolbeg Pharma PLC (POLB.L)

6.50 0.00 (0.00%)
At close: October 30 at 5:38:00 PM GMT
Chart Range Bar
Loading chart for POLB.L
  • Previous Close 6.50
  • Open 6.30
  • Bid 6.30 x --
  • Ask 6.70 x --
  • Day's Range 6.30 - 6.60
  • 52 Week Range 3.30 - 9.30
  • Volume 403,346
  • Avg. Volume 2,289,120
  • Market Cap (intraday) 49.623M
  • Beta (5Y Monthly) 1.84
  • PE Ratio (TTM) --
  • EPS (TTM) -0.01
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 19.00

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.

www.poolbegpharma.com

15

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

POLB.L
62.50%
FTSE 100 (^FTSE)
8.04%

1-Year Return

POLB.L
71.05%
FTSE 100 (^FTSE)
9.94%

3-Year Return

POLB.L
5.11%
FTSE 100 (^FTSE)
46.43%

5-Year Return

POLB.L
38.68%
FTSE 100 (^FTSE)
48.25%

Analyst Insights

View More

Analyst Price Targets

19.00
19.00 Average
6.50 Current
19.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -38.73%

  • Return on Equity (ttm)

    -58.54%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -5.46M

  • Diluted EPS (ttm)

    -0.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.82M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.49M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: